The dangers of long-term aripiprazole are actually very rare or mild, and may be manifested in causing metabolic aspects such as blood glucose and lipids in patients, as well as effects on blood pressure and cardiovascular. Monitoring of the patient’s weight and body mass index, as well as the patient’s blood glucose, lipids, blood pressure, and electrocardiogram, are mandatory at the beginning of treatment. In addition, BMI should be monitored monthly after the start of treatment and quarterly after three consecutive months. For those who are obese or have high blood glucose, high blood pressure, or high blood lipids, consider testing fasting blood glucose and blood lipids every month for several months. Then every three months to six months, monitor the blood pressure and electrocardiogram, if no abnormalities are found, long-term aripiprazole consumption is possible.